Monster Microcaps Alert to VICL shareholders. Clean Energy Technologies Moving broke out 4 weeks ago and is beginning to move again - CETY - price today $.02. Price target $.20 by year end. Clean Energy Technologies. CETY recently announced expansion with their Europe Sales and Service Center for Europe new sales and to serve 65 existing customers with CETY’s General Electric clean energy Heat Recovery Systems and just announced they have already sold the first of SEVERAL HUNDRED units to come over next 24 months.
Each CETY Heat Recovery System sells for $300,000 and market demand is several BILLION DOLLARS.
CETY purchased Heat Recovery Systems Division from General Electric and products are now very attractive to huge unmet markets and can achieve over $250 million in sales within the next 2 years. Demand for conversion of wasted heat to electrical energy in big applications is VERY LARGE AND UNMET.
Clean Energy Technologies, Inc. Secures New Order for Waste Biomass Application in Europe
COSTA MESA, Calif., July 12, 2017 /PRNewswire/ -- Clean Energy Technologies, Inc. (CETY) announced today that its subsidiary Heat Recovery Solutions has secured a new Clean CycleTM generator order for a Waste Biomass application in Europe. Growing d
Finally, some volume.It is nice to see that we are trading the stock of this company.Any forthcoming news that anybody wants to share. please post if you know why the stock is moving today.
if end of the week VL presentation positive I think this company should worth at least 100 million usd or 4x today share price
Do you think this thing is done selling? Showing us a buy signal now on VICL? if you guys have questions you should ask awesom-eSTOCKS. They often respond to my emails which is helpful.
I turn positive on vical. so many iron rods in the fire. if any turn positive it will make a tremendous comeback. I think they have a good shot specially on herpes and fungus. also that anges collaboration must have some legs.
Candida auris is an emerging fungus that presents a serious global health threat. C. auris is a drug resistant strain of fungus fatal 60% of the time in humans. It can survive for weeks on surfaces and for months on your skin. It is showing up in U.S. hospitals at an increasing rate and there are no anti-fungals to treat it. VL-2397 has a unique mechanism to attack fungi that are resistant to the other anti-fungals and could turn out to be our only hope.
Vical announced an update of HSV-2 and antifungal programs during Research & Development Day on Tuesday, May 2, 2017.
Received an alert this am about $VICL from http://yugestocks.com/?s=VICL, you may want to take a look. Making money investing. Hutchins' law: you can't out-talk a man who knows what he's talking about.
Yuge Stocks: Trading Stocks and Making Money
Stock alerts from the Yuge Stocks. Stock trading, making money and always looking for the next big money maker.
Vical has completed the enrollment Phase 2 HSV-2 vaccine.
Original paid in capital and surplus $459 million vs $23.3 million current market cap ( selling now for 5 cents on the dollar) well what is next?????
Anges reported 100% life sparing effectiveness using their equine antibodies in Ebola infected mice.There may be no limit to how many diseases equine antibodies could end up treating....malaria?....cancer? Reuters says Anges and Vical have agreed to protect IP rights so expect some new patent applications soon.
Anges announced the development of gene therapy drug for the treatment of chronic hepatitis B in cooperation with Vical.
Low float & high volume. The chart looks strong if it pick up more vol pm it's breaking $4.
The upside potential for VICL just got a whole lot more interesting. This is so frustrating trying to find trade ideas. I've subscribed to some email newsletters which helps me with new stock ideas. a.awesomestocks is the one i like best.
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.8 In other words, the correlation coefficient of the other stoc
MONSTER NEWS WITHIN DAYS...2000%++ UPSIDE POTENTIAL
AQSZF (MC $15 M) is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $15 Million ,this unknown stock is definitely one of the cheapest Biotech in the sector .Stock should be at minimum $2+ right now .
Aequus Successfully Completes Dosing in Second Proof of Concept Clinical Trial of Transdermal Aripiprazole Patch... The Company expects to report topline results from this multi-dose study in the first quarter of 2017.
Market Cap :US$ 15 Million Cash $4.1 Million << enough untill mid 2018 Price 0.21
File for CDN approval of Oxcarbazepine XR in 1H 2017
Additional Product Deals in 2017
Partnership for AQS1301 in 2017
Two products launches to date (Tacrolimus IR and Vistitan™)
3 long-acting, transdermal programs in development, on track to file NDA in 2018
Aequus has an expanding product pipeline of drugs in Canada. Revenues and cash flows are increasing and products produce a 50% margin, Edward Karr, Managing ...
Someone must have translated the Anges News Release on the equine Ebola vaccine success.
VICL has just seen the last of the selling. Looks like a potential push higher with a forward (P/E) of 33.29. goog allerted a new stock just now. going to check it out.
whats up ? if this works it will be a great come back story
anyone get this information from yesterday ?
company will provide an overview of its technologies, development programs, and outlook at 2:15 p.m. PT on Thursday, March 2, at Biocom's Global Life Science Partnering Conference (La Jolla – March 1-2). A copy of the presentation will be available through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.